Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 13 clinical trials
None
Study of ASTX727 vs IV Decitabine in MDS CMML and AML

Multicenter, randomized, open-label, crossover PK study of ASTX727 versus IV decitabine. Adult subjects who are candidates to receive IV decitabine will be randomized 1:1 to receive the ASTX727

blast cells
astx727
induction chemotherapy
chronic myelomonocytic leukemia
conjugated bilirubin
  • 269 views
  • 27 Jan, 2021
  • 93 locations
None
Phase 1-2 Study of Low Dose ASTX727 (ASTX727 LD) in Lower Risk MDS

Multicenter, open-label study of various ASTX727 LD doses and schedules to assess safety, pharmacodynamics, pharmacokinetics, and hematologic response in subjects with IPSS risk category of low

decitabine
blood transfusion
  • 26 views
  • 29 Sep, 2021
  • 27 locations
None
ASTX727 in Recurrent/Progressive Non-enhancing IDH Mutant Gliomas

this research study is evaluating the highest dose of ASTX727 that can be administered safely to recurrent/progressive non-enhancing IDH mutant gliomas patients.

  • 3 views
  • 25 Jan, 2021
None
A Study of ASTX727 in People With Malignant Peripheral Nerve Sheath Tumors (MPNST)

The purpose of this study is to see whether the study drug ASTX727 is an effective treatment for people who have MPNST with a PCR2 mutation. ASTX727 is a combination of two drugs

  • 0 views
  • 27 Jun, 2021
  • 7 locations
None
Pharmacokinetics Safety and Efficacy of ASTX727 in Combination With Venetoclax in Acute Myeloid Leukemia (AML)

The Phase 1 portion of this study is a single-arm, open-label, multicenter, non-randomized interventional study to evaluate the pharmacokinetic (PK) interaction, safety, and efficacy of ASTX727

carbon monoxide
induction chemotherapy
ejection fraction
decitabine
venetoclax
  • 0 views
  • 05 Oct, 2021
  • 7 locations
None
Venetoclax and ASTX727 for the Treatment of Relapsed Refractory or Newly Diagnosed Acute Myeloid Leukemia

This phase II trial studies the possible benefits of venetoclax and ASTX727 in treating patients with acute myeloid leukemia that has come back (relapsed) or does not respond to treatment

  • 0 views
  • 15 Mar, 2021
  • 1 location
None
Testing the Combination of Belinostat and SGI-110 (Guadecitabine) or ASTX727 for the Treatment of Unresectable and Metastatic Conventional Chondrosarcoma

This phase II trial studies the effect of belinostat and SGI-110 (guadecitabine) or ASTX727 in treating patients with conventional chondrosarcoma that cannot be removed by surgery (unresectable

  • 0 views
  • 05 Dec, 2021
  • 22 locations
None
ASTX727 Venetoclax and Gilteritinib for the Treatment of Newly Diagnosed Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

This phase I/II trial studies the best dose of gilteritinib given together with ASTX727 and venetoclax and the effect of ASTX727, venetoclax, and gilteritinib in treating patients with FLT3

carbon monoxide
ejection fraction
decitabine
venetoclax
myeloid leukemia
  • 0 views
  • 25 Aug, 2021
  • 1 location
None
Study of ASTX727 Plus Talazoparib in Patients With Triple Negative or Hormone Resistant/HER2-negative Metastatic Breast Cancer

This is a Phase I study to test the safety of a combination of ASTX727 with talazoparib in patients with triple negative breast cancer or hormone resistant/HER2-negative metastatic breast cancer

corticosteroids
neutrophil count
hormone therapy
HER2
stage iv breast cancer
  • 1 views
  • 07 Oct, 2021
  • 2 locations
None
Testing Oral Decitabine and Cedazuridine (ASTX727) in Combination With Venetoclax for Higher-Risk Acute Myeloid Leukemia Patients

This phase Ib/II trial studies the effects of ASTX727 (decitabine and cedazuridine) in combination with venetoclax in treating patients with higher-risk acute myeloid leukemia patients who do

direct bilirubin
ejection fraction
decitabine
cytarabine/daunorubicin
venetoclax
  • 0 views
  • 19 Nov, 2021
  • 1 location